Suppr超能文献

鉴定一种对K64血清型具有特异性的解聚酶:在荚膜分型和治疗中的潜在应用

Identification of a Depolymerase Specific for K64-Serotype Potential Applications in Capsular Typing and Treatment.

作者信息

Li Jiayin, Sheng Yueying, Ma Ruijing, Xu Mengsha, Liu Fuli, Qin Rong, Zhu Mingxi, Zhu Xianchao, He Ping

机构信息

Department of Medical Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

College of Medical Technology, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.

出版信息

Antibiotics (Basel). 2021 Feb 1;10(2):144. doi: 10.3390/antibiotics10020144.

Abstract

Carbapenem-resistant (CRKP), one of the major nosocomial pathogens, is increasingly becoming a serious threat to global public health. There is an urgent need to develop effective therapeutic and preventive approaches to combat the pathogen. Here, we identified and characterized a novel capsule depolymerase (K64-ORF41) derived from phage SH-KP152410, which showed specific activities for K64-serotype. We showed that this depolymerase could be used in the identification of K64 serotypes based on the capsular typing, and the results agreed well with those from the conventional serotyping method using antisera. From this study, we also identified K64 mutant strains, which showed typing discrepancy between -sequencing based genotyping and depolymerase-based or antiserum-based typing methods. Further investigation indicated that the mutant strain has an insertion sequence (IS) in , which led to the alteration of the capsular serotype structure. We further demonstrated that K64-ORF41 depolymerase could sensitize the bacteria to serum or neutrophil killing by degrading the capsular polysaccharide. In summary, the identified K64 depolymerase proves to be an accurate and reliable tool for capsular typing, which will facilitate the preventive intervention such as vaccine development. In addition, the polymerase may represent a potential and promising therapeutic biologics against CRKP-K64 infections.

摘要

耐碳青霉烯类肺炎克雷伯菌(CRKP)是主要的医院病原体之一,日益成为全球公共卫生的严重威胁。迫切需要开发有效的治疗和预防方法来对抗这种病原体。在此,我们鉴定并表征了一种源自噬菌体SH-KP152410的新型荚膜解聚酶(K64-ORF41),它对K64血清型具有特异性活性。我们表明,这种解聚酶可用于基于荚膜分型的K64血清型鉴定,结果与使用抗血清的传统血清分型方法的结果高度一致。通过这项研究,我们还鉴定出了K64突变株,其在基于测序的基因分型与基于解聚酶或抗血清的分型方法之间存在分型差异。进一步研究表明,突变株在[具体位置]有一个插入序列(IS),这导致了荚膜血清型结构的改变。我们进一步证明,K64-ORF41解聚酶可通过降解荚膜多糖使细菌对血清或中性粒细胞杀伤敏感。总之,鉴定出的K64解聚酶被证明是一种准确可靠的荚膜分型工具,这将有助于疫苗开发等预防性干预措施。此外,该解聚酶可能代表一种针对CRKP-K64感染的潜在且有前景的治疗性生物制品。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7912862/9dc545e74136/antibiotics-10-00144-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验